key: cord-0785575-qdnfsc7p
authors: Chapman, Laura RM; Oswald, Cecilia; Cain, Lucy E; Araya, Milica; Coulits, Nelly; Maurice, Lucy C; McCleary, Karen; Moses, Jonathan; Mitchell, Richard; OBrien, Tracey A; Wright, Felicity A; Trickett, Annette; Nelson, Adam S
title: 622 Donor Selection in a Geographically Isolated Country during the COVID-19 Pandemic
date: 2022-03-31
journal: Transplantation and Cellular Therapy
DOI: 10.1016/s2666-6367(22)00780-1
sha: 060c8d9d8ac16e0e854071d9995a16f518ac6a9d
doc_id: 785575
cord_uid: qdnfsc7p

nan

Coronavirus SARS CoV-2 (COVID-19) was declared an international pandemic by WHO on March 11 2020. It has placed an unprecedented impact on healthcare systems globally, including the BMT community and resources on local facilities. Australia is geographically isolated country, of a similar size to the USA, with a population of 24 million. Australia's remoteness has been further highlighted during the COVID-19 pandemic, with the government closing international borders. Strict quarantine requirements on arrival have also been mandated. This has had a significant impact on accessing fresh, unrelated donor (URD) products from overseas, with couriers unable to enter the country. Methods, intervention, and analysis: Allogeneic hematopoietic progenitor cell (HPC) transplants performed at Sydney Children's Hospital during the pandemic were compared to 2016 -2019 data. Donor source, number and country of origin for fresh URD products were scrutinized to determine whether COVID-19 had an impact on donor selection at our center. 

The median number of fresh URD products administered is 6 per year (accounting for 25% of allogenic activity, table 1), with 91.5% of URD being from overseas collection centers. In 2020, 4 fresh overseas products were given prior to the declaration of the pandemic, after which overseas fresh collections were ceased. In 2021, a single overseas cryopreserved URD product was given, with no fresh URD products. The median number of unrelated cord blood (UCB) infusions is 8 per year (35%). 10 UCB infusions occurred from January -September 2021. The majority of URD products used were UCBs, with an increase in % of UCB products during the pandemic (pre pandemic 30%, during pandemic 54%). Within the related cohort, % haplos have increased from 13% of related grafts pre-pandemic to 27% of related grafts during the pandemic at our center, due to lack of URD or UCB availability. Discussion and implications: Although COVID-19 has not had a direct impact on our BMT service, modifications to centers decision making and local resourcing, such as the use of cryopreserved products, has been beneficial in a remote country during the COVID-19 pandemic.

CAR-Associated Hemophagocytic Lymphohistiocytosis (HLH) with Use of Commercial Tisagenlecleucel in the Pediatric Real World CAR Consortium (PRWCC): Risk Factors and Outcomes Kevin O. McNerney

MD 15 ; Nicole Karras, MD 16

Center for Cancer and Blood Disorders, Children's National Hospital

Cincinatti, OH; 10 Pediatrics, Division of Hematology/ Oncology/Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago

Division of Pediatric Hematology, Oncology, and Stem Cell Transplantation